Pharmaceutical

Acumen and Lonza to produce Alzheimer’s drug sabirnetug

Acumen has entered a partnership with Lonza to further the development of sabirnetug, a potential treatment for Alzheimer's disease.

Apr 7, 2024 - 00:00
Acumen and Lonza to produce Alzheimer’s drug sabirnetug
Acumen has entered a partnership with Lonza to further the development of sabirnetug, a potential treatment for Alzheimer's disease.
Read the original article

Tags:

Previous Article

England’s MMR vaccinations up 23% following NHS initiative

Next Article

MiNA and Nippon Shinyaku enter RNAa therapeutics deal

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Dana-Farber cancer researchers moving to retract one paper, correct others in broad investigation of manipulated data

STAT+: Dana-Farber cancer researchers moving to retract...

Jan 20, 2024

Vertex secures CHMP nod for Casgevy approval in Europe

Vertex secures CHMP nod for Casgevy approval in Europe

Dec 18, 2023

Lisata shares pipeline update of anticancer lead candidate drug

Lisata shares pipeline update of anticancer lead candid...

Jun 27, 2023